Hypothesis:
Intensive risk-adjusted follow-up leads to improved resectability of tumor recurrences and better overall survival among patients who have undergone surgery for colorectal cancer.
Design:
Long-term observational single-center study.
Setting:
University of Pisa, Pisa, Italy.
Patients:
One hundred eight disease-free patients who had undergone surgery for colorectal cancer were submitted to long-term follow-up with the serum CEA, TPA, CA19.9, and CA72.4 tumor marker (TM) panel and abdominal ultrasonography.
Main Outcome Measures:
Sensitivities and specificities of TMs, abdominal ultrasonography, and abdominal and chest computed tomography (CT); the median survival among patients operated on and those not operated on and the cumulative 5-year overall survival among the entire group.
Results:
Twenty-two patients with asymptomatic colorectal cancer recurred 32 times. The CEA, TPA, CA19.9, CA72.4, and TM panel sensitivities were 46.9%, 34.4%, 9.4%, 9.4%, and 81.0%, respectively, and the mean (SD) lead times before confirmation of recurrence were 4.3 (4.8), 4.1 (4.7), 8.3 (10.9), 5.0 (7.0), and 5.3 (5.8) months, respectively. Abdominal and chest CT sensitivities were 100.0%. Among 86 patients without recurrence, specificities of the TM panel and all panel markers were 100.0%, while specificities of abdominal ultrasonography, abdominal CT, and skeletal CT were 99.9%, 99.0%, and 100.0%, respectively. The median survival after first recurrence was 16 months (range, 3-48 months) for 8 patients with recurrence who did not undergo second-line surgery. Among 14 remaining patients who underwent metastasectomy, the median survival after first recurrence was 37 months (range, 12-187 months; P = .03). Among the entire group of 108 patients, the cumulative 5-year overall survival was 88.7%.
Conclusions:
Long-term intensive risk-adjusted monitoring using the CEA, TPA, CA19.9, and CA72.4 TM panel and abdominal ultrasonography allows early detection of most recurrences. Patients can then undergo radical metastasectomy, with potentially improved overall survival.
Citing Articles
Recent Technologies towards Diagnostic and Therapeutic Applications of Circulating Nucleic Acids in Colorectal Cancers.
Chung J, Xiao S, Gao Y, Soung Y
Int J Mol Sci. 2024; 25(16).
PMID: 39201393
PMC: 11354501.
DOI: 10.3390/ijms25168703.
Significance of carcinoembryonic antigen detection in the early diagnosis of colorectal cancer: A systematic review and meta-analysis.
Wang R, Wang Q, Li P
World J Gastrointest Surg. 2024; 15(12):2907-2918.
PMID: 38222002
PMC: 10784816.
DOI: 10.4240/wjgs.v15.i12.2907.
N-myristoyltransferase 2-based Blood Test for the Detection of Colorectal Adenomatous Polyps and Cancer.
Rathinagopal T, Bhanot S, Yegrov S, Min J, Hu N, Fang J
Ann Surg Open. 2023; 3(1):e117.
PMID: 37600093
PMC: 10431588.
DOI: 10.1097/AS9.0000000000000117.
A Novel Urinary miRNA Biomarker for Early Detection of Colorectal Cancer.
Iwasaki H, Shimura T, Kitagawa M, Yamada T, Nishigaki R, Fukusada S
Cancers (Basel). 2022; 14(2).
PMID: 35053622
PMC: 8773893.
DOI: 10.3390/cancers14020461.
Overexpression of GDP dissociation inhibitor 1 gene associates with the invasiveness and poor outcomes of colorectal cancer.
Xie X, Lin H, Zhang X, Song P, He X, Zhong J
Bioengineered. 2021; 12(1):5595-5606.
PMID: 34515625
PMC: 8806759.
DOI: 10.1080/21655979.2021.1967031.
The Pivotal Player: Components of NF-κB Pathway as Promising Biomarkers in Colorectal Cancer.
Martin M, Sun M, Motolani A, Lu T
Int J Mol Sci. 2021; 22(14).
PMID: 34299049
PMC: 8303169.
DOI: 10.3390/ijms22147429.
Diagnostic accuracy of follow-up tests for detecting colorectal cancer recurrences in primary care: A systematic review and meta-analysis.
Liemburg G, Brandenbarg D, Berger M, Duijts S, Holtman G, de Bock G
Eur J Cancer Care (Engl). 2021; 30(5):e13432.
PMID: 33704843
PMC: 8518902.
DOI: 10.1111/ecc.13432.
Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
Su P, Lai W, Liu L, Zeng Y, Xu H, Lan Q
Clin Transl Gastroenterol. 2021; 11(12):e00265.
PMID: 33512811
PMC: 7743843.
DOI: 10.14309/ctg.0000000000000265.
Correlation between tumor marker CA72-4 and prognosis of patients with gastric cancer: A protocol for systematic review and meta-analysis.
Li M, Xue F, Yang J, Pan X
Medicine (Baltimore). 2020; 99(52):e23723.
PMID: 33350753
PMC: 7769321.
DOI: 10.1097/MD.0000000000023723.
Exosomal MALAT1 sponges miR-26a/26b to promote the invasion and metastasis of colorectal cancer via FUT4 enhanced fucosylation and PI3K/Akt pathway.
Xu J, Xiao Y, Liu B, Pan S, Liu Q, Shan Y
J Exp Clin Cancer Res. 2020; 39(1):54.
PMID: 32209115
PMC: 7092616.
DOI: 10.1186/s13046-020-01562-6.
Colorectal Cancer Biomarkers - A New Trend in Early Diagnosis.
Toma S, Ungureanu B, Patrascu S, Surlin V, Georgescu I
Curr Health Sci J. 2019; 44(2):140-146.
PMID: 30746161
PMC: 6320460.
DOI: 10.12865/CHSJ.44.02.08.
Colorectal Cancer Blood-Based Biomarkers.
Hauptman N, Glavac D
Gastroenterol Res Pract. 2017; 2017:2195361.
PMID: 29147109
PMC: 5632863.
DOI: 10.1155/2017/2195361.
Exosomes As Potential Biomarkers and Targeted Therapy in Colorectal Cancer: A Mini-Review.
Hon K, Abu N, Mutalib N, Jamal R
Front Pharmacol. 2017; 8:583.
PMID: 28894420
PMC: 5581359.
DOI: 10.3389/fphar.2017.00583.
Quantitative proteome analysis of colorectal cancer-related differential proteins.
Zhang Y, Liu Y, Ye Y, Shen D, Zhang H, Huang H
J Cancer Res Clin Oncol. 2016; 143(2):233-241.
PMID: 27659785
DOI: 10.1007/s00432-016-2274-5.
Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
Lech G, Slotwinski R, Slodkowski M, Krasnodebski I
World J Gastroenterol. 2016; 22(5):1745-55.
PMID: 26855534
PMC: 4724606.
DOI: 10.3748/wjg.v22.i5.1745.
Blood CEA levels for detecting recurrent colorectal cancer.
Nicholson B, Shinkins B, Pathiraja I, Roberts N, James T, Mallett S
Cochrane Database Syst Rev. 2015; (12):CD011134.
PMID: 26661580
PMC: 7092609.
DOI: 10.1002/14651858.CD011134.pub2.
Nodule and eminence on frenulum labii superioris: diagnostic markers for metastatic colorectal cancer.
Cao R, Wang L, Chi J, Wu X
Chin J Integr Med. 2014; 20(6):416-9.
PMID: 24952169
DOI: 10.1007/s11655-014-1681-1.
Opposite variation tendencies of serum CA724 levels in patients with colon and rectal carcinoma.
Zhu Z, Chen Z, Chen C, Yang Z, Xuan W, Hou Y
Mol Clin Oncol. 2014; 2(1):139-145.
PMID: 24649323
PMC: 3916083.
DOI: 10.3892/mco.2013.208.
Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.
Suppiah A, Greenman J
World J Gastroenterol. 2013; 19(29):4651-70.
PMID: 23922463
PMC: 3732838.
DOI: 10.3748/wjg.v19.i29.4651.
Physician follow-up and observation of guidelines in the post treatment surveillance of colorectal cancer.
Vargas G, Sheffield K, Parmar A, Han Y, Brown K, Riall T
Surgery. 2013; 154(2):244-55.
PMID: 23889952
PMC: 3839939.
DOI: 10.1016/j.surg.2013.04.013.